English
中文
CAS:284461-73-0
Storage:Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
Manual Download
Examples of using this product（for reference only）
In Vitro：
Cell （4T1, CT26, and B16-F10 cells；0-20μM Sorafenib/Srf；48h）:
4T1, CT26, and B16-F10 cells (2000 cells per well) were seeded into 96-well plates and cultured for 12 h under normoxic conditions. The cells were further cultured under normoxic or hypoxic conditions for another 12 h. The cells were treated with differentconcentrations of free Srf under normoxic or hypoxic conditions for 48 h (n = 3). Next, 35 mL MTT (5 mg/mL) was added to96-well plates and incubated for 4 h. The MTT solutions were replaced with dimethyl sulfoxide (DMSO), and cell viability was testedusing a microplate reader at 490 nm.
Reference：
Wang Z, Zhang S, Kong Z, Li S, Sun J, Zheng Y, He Z, Ye H, Luo C. Self-adaptive nanoassembly enabling turn-on hypoxia illumination and periphery/center closed-loop tumor eradication. Cell Rep Med. 2023 Apr 18;4(4):101014. doi: 10.1016/j.xcrm.2023.101014. PMID: 37075700; PMCID: PMC10140616.
